1- TUMS
2- Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran , hraghai@sina.tums.ac.ir
3- Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
4- Evidence Based Medicine Research Center, Endocrinology and Metabolism Clinical Sciences Institute Tehran University of medical Sciences. Tehran, Iran
5- TUMS/ EMRI
Abstract: (64 Views)
Background: Vitamin D (vitD3) deficiency is common in Iran. Although there are several studies on therapeutic doses of vitD3, the optimal dose is to be evolved. we compared the effects of high dose supplemental vitD3 versus its recommended dose on the serum level of 25(OH)D.
Methods: This clinical trial study is performed at Endocrine & Metabolism Research Institute in Shariati Hospital within 2008-2009. The subjects were osteopenic women older than 50 years who had been referred to Bone Densitometry laboratory. They were received either (group P) 50000u vitD3 weekly for 3 months then monthly for another 9 months, or (group M) 800u vitD3 daily for one year. 1000 mg calcium carbonate was given to both groups. Serum 25(OH)D, Calcium, Phosphorus, PTH was checked at base, 3rd, 6th and 12th month. 24h Urine for calcium was collected before and at the end of trial.
Results: Serum 25(OH)D level was significantly higher in group P at 3rd month (p<0.05), but it gradually declined and there was not statistically difference to group M. PTH decreased in both groups. Urine calcium to creatinine ratio did not rise in both groups.
Conclusion: vitD3 supplement at doses of 50000u weekly for 3 months then monthly for another 9 months as compare to 800u vitD3 daily for one year increases serum 25(OH)D at higher level without causing hypercalcemia and hypercalciuria, but it seems that more frequent doses in monthly period would be required to maintain the optimal 25(OH)D level.
Type of Study:
Research |
Subject:
Special Received: 2024/09/11 | Accepted: 2024/09/14